Keyword: Lonza

News

Lonza Announces New Mid-Term Guidance 2024 – 2028

17.10.2023 -

At its Capital Markets Day in Visp, Switzerland, Lonza shared a detailed update on its strategic priorities and provided new Mid-Term Guidance for 2024 to 2028.

Chemistry & Life Sciences

Spray Drying for Inhalation: the Challenges of Scale-up

16.10.2023 -

When developing an inhaled powder formulation, the drug particles’ properties are critical to successful delivery to the deep lung. The aerodynamic diameter is the key...

News

Lonza Increases Capacity for Antibody-Drug Conjugates at Visp, Switzerland

06.10.2023 -

Swiss contract development and manufacturing organization (CDMO) Lonza is extending a long-term collaboration with an unnamed major global biopharmaceutical partner...

Research / Laboratory

Successful Clinical to Commercial Bioconjugate Manufacturing

Lonza AG -

Ever since antibody drug conjugates (ADCs) were first reported in the 1970s, the field of bioconjugation has found itself in a constant state of evolution.

News

Lonza-CEO Ruffieux to Leave Swiss CDMO

18.09.2023 -

Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September.

Markets & Companies

The Evolution of CDMOs

13.09.2023 -

Contract development and manufacturing organizations (CDMOs) are a crucial part of the life sciences industry. Strangely, despite its current prominence, the CDMO...

News

Lonza, Vertex Break Ground on New US Cell Therapy Plant

05.09.2023 -

Last week, Lonza and Vertex Pharmaceuticals broke ground on a new US facility in Portsmouth, New Hampshire, to manufacture cell therapies for diabetes.

Research / Laboratory

Improving ADC Production and Purification

Lonza AG -

How Optimizing Process Parameters Can Improve Scalability and Manufacturability of a Cytotoxic Antibody Drug Conjugate.